Table 2.
Comparison of clinical manifestations between AML patients and Foxo3 expression
| Patient’s parameters | High (n = 66) | Low (n = 56) | P value |
|---|---|---|---|
| Sex, male/female | 40/26 | 34/22 | 1.0 |
| Median age, years (range) | 59 (15–87) | 54.5 (10–93) | 0.128 |
| Median WBC, ×109/L (range) | 14.5 (0.8–528) | 26.75 (0.3–197) | 0.313 |
| Median hemoglobin, g/L (range) | 74.5 (34–138) | 78.5 (49–135) | 0.134 |
| Median platelets, ×109/L (range) | 41 (3–264) | 39.5 (5–415) | 0.921 |
| BM blasts, % (range) | 46.25 (5.5–99) | 42 (1–94.5) | 0.197 |
| CR (−/+) | 33/30 | 29/24 | 0.853 |
| FAB classification | 0.428 | ||
| M0 | 1 (1.5%) | 0 (0%) | |
| M1 | 6 (9.1%) | 2 (3.6%) | |
| M2 | 29 (43.9%) | 19 (33.9%) | |
| M3 | 8 (12.2%) | 15 (26.8%) | |
| M4 | 13 (19.7%) | 12 (21.4%) | |
| M5 | 8 (12.1%) | 7 (12.5%) | |
| M6 | 1 (1.5%) | 1 (1.8%) | |
| Karyotype classification | 0.666 | ||
| Favorable | 18 (27.3%) | 19 (33.9%) | |
| Intermediate | 37 (56.1%) | 28 (50%) | |
| Adverse | 8 (12.1%) | 7 (12.5%) | |
| No data | 3 (4.5%) | 2 (3.6%) | |
| Karyotype | 0.423 | ||
| normal | 27 (40.9%) | 20 (35.7%) | |
| t(8;21) | 8 (12.1%) | 4 (7.1%) | |
| t(15;17) | 9 (13.6%) | 15 (26.8%) | |
| 11q23 | 0 (0) | 0 (0) | |
| complex | 8 (12.1%) | 5 (8.9%) | |
| others | 11 (15.2%) | 10 (30.4%) | |
| No data | 3 (4.5%) | 2 (3.6%) | |
| Gene mutation | |||
| CEBPA (+/−) | 10/51 | 3/41 | 0.229 |
| NPM1 (+/−) | 4/57 | 3/41 | 1.00 |
| FLT3-ITD (+/−) | 7/54 | 5/39 | 1.00 |
| KIT (+/−) | 2/59 | 2/42 | 1.00 |
| N/K-RAS (+/−) | 8/53 | 2/42 | 0.187 |
| IDH1/2 (+/−) | 2/59 | 2/42 | 1.00 |
| DNMT3A (+/−) | 4/57 | 5/39 | 0.487 |
| U2AF1 (+/−) | 2/59 | 1/43 | 1.00 |
WBC white blood cells, FAB French-American-British classification, AML acute myeloid leukemia, CR complete remission. Percentage was equal to the number of mutated patients divided by total cases in each group